Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Tanya Yanovsky

Psychiatry Waltham, MA Medical Doctor

NPI 1295719748 CMS profile 239537

20 Hope Ave, Suite G05, Waltham, MA 02453

Open in the dashboard

General payments

$966

43 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Tanya Yanovsky of Waltham, MA is reported in the CMS Open Payments database as having received $966 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $21 1
2020 General $214 7
2019 General $730 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanya Yanovsky
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Tanya Yanovsky were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Tanya Yanovsky Psychiatry median Middle half National median
2019 $730 $184 $59–$605 $163
2020 $214 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $21 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Allergan Inc. $256 10 payments
  2. Otsuka America Pharmaceutical, Inc. $198 7 payments
  3. Janssen Pharmaceuticals, Inc $127 2 payments
  4. Lundbeck LLC $97 6 payments
  5. Sunovion Pharmaceuticals Inc. $85 4 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $73 5 payments
  7. Neurocrine Biosciences, Inc. $50 4 payments
  8. Shire North American Group Inc $29 2 payments
  9. Ironshore Pharmaceuticals Inc. $29 2 payments
  10. AbbVie, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $966 43 payments
Products named General payments · program years 2019–2022
  1. VRAYLAR $256 10 payments
  2. REXULTI Psychiatry $182 6 payments
  3. SPRAVATO $127 2 payments
  4. REXULTI Psychiatry $97 6 payments
  5. LATUDA $85 4 payments
  6. Trintellix Central Nervous System (CNS) $51 4 payments
  7. INGREZZA $50 4 payments
  8. VYVANSE $29 2 payments
  9. Jornay PM 20mg capsules (Bottle of 100) $29 2 payments
  10. TRINTELLIX Neuroscience $22 1 payment
  11. Other $48 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,754

Median for Psychiatry: 574

Drug cost

$88,871

Median for Psychiatry: $27,624

Branded share of claims

24.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 23 $21,520
Lurasidone Hcl Generic 14 $17,850
Vraylar Cariprazine Hcl Brand 11 $15,658
Duloxetine Hcl Generic 131 $7,097
Trazodone Hcl Generic 120 $2,292
Bupropion Xl Bupropion Hcl Brand 91 $2,021
Venlafaxine Hcl Er Venlafaxine Hcl Brand 105 $1,906
Methylphenidate Er (La) Methylphenidate Hcl Brand 11 $1,692
Buspirone Hcl Generic 46 $1,600
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 47 $1,550

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$26,409

Medicare's payments for the services billed

Medicare patients

93

Average age 72

Services billed

274

74 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 57%
Arthritis 47%
Osteoporosis 24%
Diabetes 19%
Chronic kidney disease 18%
Ischemic heart disease 17%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record